New Product Will Target Weight Loss and Be Available in the U.S.
LONDON, UNITED KINGDOM--(Marketwired - Mar 2, 2016) - Plandaí Biotechnology, Inc. (
Callum Cottrell-Duffield, Vice President of Sales and Marketing for Plandaí Biotechnology, stated, "The Grenade® Thermo Detonator product combines the known benefits of Phytofare® catechins with a powerful capsasin. The synergy of the two should provide a significant thermogenesis effect, which is a critical component of weight loss. Following an initial release in Europe, Grenade® expects to commence shipping the Thermo Detonator product to the United States where they already have established distribution in major retailers."
Grenade® is an innovative and trusted sports performance and energy brand that has grown rapidly since its launch in 2010. Now selling Grenade® products to over 100 countries, Grenade has a huge following that includes professional athletes, fitness enthusiasts and military personnel worldwide. Grenade® has been recognized with numerous awards both within the sports nutrition sector and in the global business arena. As a result, Grenade® is not only widely regarded as one of the world's fastest growing sports performance/weight management brand, but also as one of the most exciting sports nutrition companies in the market today. Grenade products were awarded the European Diet & Weight Management Product of the Year in 2013, 2014 and 2015.
For additional information, please visit www.grenade.com.
About Plandaí Biotechnology, Inc.
Plandaí Biotechnology, Inc. and its subsidiaries develop highly phyto-available™ extracts. Plandaí Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing its proprietary Phytofare® extracts in-house, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include beverage, cosmeceutical, wellness, nutriceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.
Safe Harbor Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Readers are advised to review our filings with the Securities and Exchange Commission that can be accessed over the Internet at the SEC's website located at http://www.sec.gov.